You Position: Home > Paper
The Japanese guidelines for the management of disseminated intravascular coagulation
( views:713, downloads:974 )
- Author:
- No author available
- Journal Title:
- CHINESE CRITICAL CARE MEDICINE
- Issue:
- 8
- DOI:
- 10.3760/cma.j.issn.1003-0603.2009.08.002
- Key Word:
- No keyword available
Abstract： 由日本血栓止血学会学术专门委员会弥散性血管内凝血(DIC)部组织撰写的"日本DIC治疗指南",按照循证医学(EBM)概念进行系统的文献检索,参考日本血液学会和日本临床血液学会专家的反馈加以修改,论述并点评了DIC的基础疾病治疗、抗凝治疗、纤溶调节治疗和补充治疗,并就其可信度分级推荐.
- [1]Janes J,Levy M,Wyncoll D,etc.Prophylactic heparin in patients with severe sepsis treated with drotrecogin alfa (activated).[J].2007,176(5).
- [2]M A, Kish.Guide to development of practice guidelines.[J].2001,32(6).
- [3]Dhainaut JF,Fisher CJ Jr,Ely EW,etc.Efficacy and safety of recombinant human activated protein C for severe sepsis.[J].2001,344(10).
- [4]Guy JS,Rossaint R,Garg R,etc.Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death.[J].2005,353(13).
- [5]R Phillip, Dellinger,Jean M, Carlet,Henry, Masur,etc.Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock.[J].2004,32(3).
- [6]Juers M,Hoffmann JN,Opal SM,etc.Treatment effects of high-dose antithrombin without concomitant heparin in patients with severe sepsis with or without disseminated intravascular coagulation.[J].2006,4(1).
- [7]Abraham E,Shu V,Zwingelstein C,etc.Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: a randomized controlled trial.[J].2003,290(2).
- [8]Girbes AR,Polderman KH.Drug intervention trials in sepsis: divergent results.[J].2004,363(9422).
- [9]Wiedermann CJ,Kaneider NC.A systematic review of antithrombin concentrate use in patients with disseminated intravascular coagulation of severe sepsis.[J].2006,17(7).
- [10]Kadohira Y,Arahata M,Hayashi T,etc.Beneficial effects of urokinase on lipopolysaccharide-induced disseminated intravascular coagulation in rats: focus on organ function and endothelin levels.[J].2005,93(4).
- [11]Heinrichs H,Singer P,Novak I,etc.Caring for the critically ill patient. High-dose antithrombin III in severe sepsis: a randomized controlled trial.[J].2001,286(15).
- [12]Ohno R,Matsuda T,Saito H,etc.Efficacy and safety of recombinant human soluble thrombomodulin (ART-123) in disseminated intravascular coagulation: results of a phase III, randomized, double-blind clinical trial.[J].2007,5(1).